Coronavirus and Care Homes

Alistair Carmichael Excerpts

Tuesday 19th May 2020 Commons Chamber

[Matt Hancock]

Yes, absolutely—being tested is the right thing to do if that is what you are asked to do. It is really important. We are rolling out testing both for people with symptoms and asymptomatic people, to try to find all the coronavirus in our care homes, to be able to trace it and then end this epidemic.

[Mr Alistair Carmichael (Orkney and Shetland) (LD) [V]]

This being Mental Health Awareness Week, can we spend some time considering and reflecting on the mental health impact that the coronavirus pandemic will have on the frontline health and social care workers charged with tackling it? In particular, would it not be a great example of the good working of our four Governments if an action plan on mental health was constructed with the support of all four Governments?

[Matt Hancock]

The right hon. Gentleman is right to raise that. This is Mental Health Awareness Week, and I have front of mind the mental health impacts of coronavirus, particularly on staff but across the board. We work closely through the chief medical officers of the four nations of the UK and between Ministers to try to ensure that clinical advice is co-ordinated. After all, it is based on the science. I am happy to look at the proposals and discuss them with the CMO.

Covid-19

Alistair Carmichael Excerpts

Tuesday 12th May 2020 Commons Chamber

[Mr Alistair Carmichael (Orkney and Shetland) (LD) [V]]

I do not always agree with the hon. Member for Wellingborough (Mr Bone), but what he said about the need for the Government to show proper respect to Parliament and to this House is correct, and I hope that it will be heard on the Treasury Bench.

I welcome the announcement by the Chancellor of the Exchequer of his intention to extend the furlough scheme. For businesses in the Northern Isles that will provide welcome clarity, which is very much needed. It will also allow us time to work out how we can build sufficient flexibility into the scheme in order to see a glide path coming out of it. However, my welcome for the announcement is very much tempered by my regret that so much of the provision that remains for self-employed people is wholly inadequate. We still have no answer for those small business people who rely on dividend income rather than a salary for their income. Although it would be complicated, surely it is not beyond the wit of man if the political will were there.

The Government are allowing too many self-employed people to be left behind. Here in the Northern Isles we particularly see that in the visitor economy, which is crucial to us. The assistance for bed and breakfast operators, or operators of self-catering accommodation, leaves too many people without the assistance they need. As my hon. Friend the Member for Caithness, Sutherland and Easter Ross (Jamie Stone) said earlier, the seasonal nature of our provision means that a support scheme that finishes at the end of August, or September or whenever it will be, simply will not be adequate in parts of the country such as ours. Those parts of the country that have seasonal tourism require a 12-month programme, or else the tourism industry that will be left to be resurrected at the end of this process will be that much weaker, and the rebuilding and recovery that much more difficult.

We all know that at some point we will need some sort of inquiry into this. I do not suggest that now is the moment to start that—obviously, the important thing at present is to deal with the job in hand—but we should be thinking about how the inquiry will be done. Without prejudging the outcome, it is pretty clear that when we look back at this time, we will realise that the response to this pandemic has been at its strongest when all four Governments of the United Kingdom have been able to work together. I commend them all for embarking on a four-nations approach right from the start, although we saw the first divergence from that this weekend, with the Prime Minister changing his messaging away from staying at home, to being alert. That is an intrinsically problematic message. It lacks clarity, but worse than that, it also lacks credibility with the population as a whole. I hope that as we go ahead, the four Governments of this country will see that not as an opportunity to score points against each other, but as a warning about the need to keep a unified message. Only with that unified message can we possibly hope to bring all four parts of this United Kingdom successfully through to the other side of this outbreak.

Covid-19 Update

Alistair Carmichael Excerpts

Tuesday 5th May 2020 Commons Chamber

[Matt Hancock]

That is a really important point. It is critical, because the overall impact of coronavirus is not just the direct morbidity—the number of people who sadly die from coronavirus itself; there is also the wider impact, including those whose treatment has been delayed owing to the necessity of ensuring that the NHS was ready to cope with coronavirus, or because, for clinical reasons, it was important to delay the treatment because there is such a virulent virus at large. We are working very hard to restore treatments for non-covid reasons. That work has started. I was able to announce last week, for instance, that fertility treatment has restarted and cancer treatment is restarting, and other elective surgeries will restart as soon as it is safe to do so.

[Mr Alistair Carmichael (Orkney and Shetland) (LD) [V]]

I am in Orkney, where I have been receiving reports from category 2 key workers who have self-referred for a covid test through the gov.uk website and been directed to testing centres in Thurso, Elgin or even Peterhead, all of which would require a journey by ferry or plane. There is local provision and the option of postal testing, so will we get the website sorted, to allow people to get the information they need, rather than be left thinking that in order to get a test they first need to get a plane or a ferry?

[Matt Hancock]

I am glad that we sorted the broad- band to Orkney, so that we could take the question. It is an important question and I will look into the specifics of it to make sure that our island communities get the appropriate response on the website. The right hon. Gentleman will appreciate that we put the testing website together at remarkable pace and so in the first iteration we were not able to address this sort of important nuance for Orkney and other island communities, but I will take that away and look at it. He mentioned the answer in substance—to get the home testing kits working for Orkney—and I am sure that there is a way through.

Covid-19

Alistair Carmichael Excerpts

Monday 16th March 2020 Commons Chamber

[Matt Hancock]

We have taken a decision on health grounds to make the changes to the advice that are deemed necessary, according to the scientific advice and the medical advice, to keep people safe. I understand that there are huge consequences from that for businesses right across the country, and my right hon. Friend the Chancellor is leading the work to support those businesses.

[Mr Alistair Carmichael (Orkney and Shetland) (LD)]

In Shetland we have 15 of the 171 confirmed cases in Scotland. That is almost 9%, from an island community of 22,000. In normal circumstances, anyone requiring intensive care in Shetland is taken by air ambulance to mainland Scotland. Because of the nature of coronavirus, we cannot do that. I understand that military assets will be engaged for that transportation, but clinicians tell me that there is no understanding of the protocols and there has not yet even been a dress rehearsal. Will the Secretary of State speak to his right hon. Friend the Secretary of State for Defence to ensure that all necessary communication happens to ensure that when the service is needed, it will work?

[Matt Hancock]

Yes, I will. We will make sure that we support people on all parts of these islands, including all islands that are part of these islands.

Oral Answers to Questions

Alistair Carmichael Excerpts

Tuesday 10th March 2020 Commons Chamber

[Mr Alistair Carmichael (Orkney and Shetland) (LD)]

14. What steps his Department is taking to support research into brain tumours.

[The Parliamentary Under-Secretary of State for Health and Social Care (Jo Churchill)]

As I say, cancer survival is our priority and that was made clear in the long-term plan. Unlike many cancers, we have not moved the dial really far enough for patients with brain cancer. To ensure better outcomes for those affected by brain tumour, we need to focus and redouble our efforts on innovative research and new methods of diagnosis and treatment. That is why we have pledged £40 million over five years to stimulate brain tumour research, working alongside the Tessa Jowell brain cancer charity.

[Mr Alistair Carmichael (Orkney and Shetland) (LD)]

That is welcome news. Ten per cent. of all cancer deaths of people under 50 are from brain tumours, but the cancer receives only 2% of the money spent on cancer research funding. The previous Government established an inquiry into this to see what more could be done. Does the Minister agree that this month, which is Brain Tumour Awareness Month, would be a good time to re-establish that inquiry?

[Jo Churchill]

I would be more than happy to meet the right hon. Gentleman to talk about his ambitions. The funding is going up and, as I have said before, it is always welcome to me when cancer charities drive awareness, so that people are more aware of the symptoms, particularly of cancers where we are not moving forward fast enough.

Medicines and Medical Devices Bill

Alistair Carmichael Excerpts

2nd reading & 2nd reading: House of Commons & Money resolution & Money resolution: House of Commons & Programme motion & Programme motion: House of Commons & Ways and Means resolution & Ways and Means resolution: House of Commons
Monday 2nd March 2020 Commons Chamber

[The Parliamentary Under-Secretary of State for Health and Social Care (Jo Churchill)]

First, let me thank all hon. Members for their support in discussing this enabling legislation. It is a pleasure to close this debate on the Medicines and Medical Devices Bill. The Bill is both a piece of legislation to future-proof our regulatory regime going forward and an opportunity to clarify and improve the one that we have now.

I am gratified that hon. Members have approached this debate with thoughtful consideration. Obviously, there is a lot more to discuss in Committee, because several themes came up during the course of this afternoon’s debate on which I can only touch now. I will take up the request of my hon. Friend the Member for Washington and Sunderland West (Mrs Hodgson) and write to her. I have not had the chance thus far to have a specific briefing with the hon. Member for Central Ayrshire (Dr Whitford), so perhaps we could do so to enable us all to understand our direction of travel.

Patient safety is not a partisan issue; it is paramount. It is what drives us to do what we do. It does not matter which side of the House we sit on, the patient is at the centre of our concern. We hope that, in going forward, we can enhance and strengthen that view and show ourselves as an exemplar to the world in the way that we conduct trials and in the way that the life science and pharmaceutical industries work. We hope to assist the whole industry in making sure that we never compromise on patient safety.

This will be the first opportunity in 40 years for the UK to make choices regarding how we regulate medicines, veterinary medicines and medical devices in the best interests of the UK now that we have left the EU. This is all part of our making sure that we transition smoothly on 1 January next year. Members from all parts of the House feel passionately about the outcome of negotiations on the future relationship. I would like to assure hon. Members that the Bill allows us, in the future, to set rules that are best for the UK, whatever the outcome of those negotiations. The Bill is important, as it makes clear the Government’s commitment to the life science sector, which is worth over £75 billion to our economy and which contributes almost 250,000 jobs to the UK. We are rightly proud of that sector, but innovations and advancement must be matched by rigorous standards to protect patients. I very much take on board the comments of the hon. Member for Twickenham (Munira Wilson), which were particularly pertinent to the experience that she brings to this House. I hope to enjoy more of that debate when we are in Committee.

The Bill sets out clear principles: ensuring patient safety; ensuring their continued access to medicines and devices; and maintaining the attractiveness of the UK as a market and a place for clinical trials. There is a delicate balance there that we must continue to strike, and the debate today demonstrates the paramount importance of all those principles. On that point, I will move on to the comments of hon. Members.

[Mr Alistair Carmichael (Orkney and Shetland) (LD)]

The provisions on veterinary medicines are essentially a straight lift from the human medicines part of the Bill. There is one significant difference, of course: animals that have been prescribed and administered medicines are put into the food chain. With regard to withdrawal periods, that, in turn, can have a significant impact on the access to markets of exported meats. Will the Minister consider later an amendment to clause 8(2), to provide at least some regard to the commercial position of the end meat products?

[Jo Churchill]

As the right hon. Gentleman knows, I am always happy to have a discussion to see whether any accommodation can be made. As far as veterinary medicines go, I should say that, unlike with human medicines, we pay attention to the environmental impact as they go through.

Medical Cannabis under Prescription

Alistair Carmichael Excerpts

Monday 20th May 2019 Commons Chamber

[Tonia Antoniazzi (Gower) (Lab)]

I thank my co-chair of the all-party group on medical cannabis under prescription, the right hon. Member for Hemel Hempstead (Sir Mike Penning), for securing this Back-Bench debate and the Backbench Business Committee for granting it on the Floor of the House. It is an honour to follow the hon. Member for Henley (John Howell).

I am committed to campaigning for medical cannabis under prescription not only for my constituents but for everyone in the UK who would benefit from access to whole-plant medical cannabis. Whole-plant cannabis contains CBD and THC. It is the interaction of both extracts taken together that provides significant relief from symptoms such as seizures, because it provides the entourage effect. The two extracts interact with the human body and produce a stronger influence than any one component alone.

We must remember the number of desperate families passed from pillar to post and blocked at every turn. Is the Minister going to sit back and watch them continue to suffer? We have families watching us from the Gallery, and their turn is now.

[Mr Alistair Carmichael (Orkney and Shetland) (LD)]

The hon. Lady makes a good point. I first became involved in this campaign in 2002 when I met my constituent, the late Biz Ivol, who had severe advanced multiple sclerosis and who told me that the pain she suffered was like having somebody draw barbed wire through her spine. For the last 17 years, we could have been exploring all the issues being ventilated tonight, but we have not. Does that not illustrate the urgency?

[Tonia Antoniazzi]

The right hon. Gentleman is absolutely right, and I will go on to talk about a very good friend of mine who suffers with MS.

Oral Answers to Questions

Alistair Carmichael Excerpts

Tuesday 15th January 2019 Commons Chamber

[Ronnie Cowan (Inverclyde) (SNP)]

5. What guidance his Department has issued to clinicians on the prescription of cannabis-based products for medicinal use.

[Mr Alistair Carmichael (Orkney and Shetland) (LD)]

13. What recent clinical advice he has sought on the licensing of cannabis oil for medicinal purposes.

[The Parliamentary Under-Secretary of State for Health and Social Care (Steve Brine)]

The Government acted swiftly to change the law to allow cannabis-based products to be prescribed for those patients who might benefit, with advice from the chief medical officer and the Advisory Council on the Misuse of Drugs. NHS England and the CMO have written to clinicians in England highlighting the interim clinical guidance available.

Oral Answers to Questions

Alistair Carmichael Excerpts

Tuesday 19th December 2017 Commons Chamber

[Mr Dunne]

My hon. Friend will be aware that last week we published the workforce strategy. One major focus was on meeting the Secretary of State’s commitment to increase the number of registered nurses by 25% and to broaden the routes into nursing. There is a commitment to expand the nursing associate role, which is helping to provide opportunities, through an alternative route, for healthcare support workers to become registered nurses.

[Mr Alistair Carmichael (Orkney and Shetland) (LD)]

T10. Possibly as many as 20,000 babies have been born with birth defects as a consequence of their mothers having used sodium valproate during pregnancy. When will mandatory warnings be given to pregnant women about the risks associated with valproate, and when will we see independent analysis of how we got to this dreadful situation?

[Steve Brine]

There is huge interest in this subject in the House. Over the past three years, there has been extensive work to communicate advice on the risks of valproate in pregnancy, through a huge number of channels, to help professionals and patients. It is evident from monitoring activities that providing health professionals with information, even when repeated constantly through multiple sources, is not changing prescribing behaviour sufficiently to minimise harm to children exposed to valproate in pregnancy. The expert working group of the Commission on Human Medicines is informing the UK position in European negotiations and advising on the national action required within the UK health system. [Interruption.] Sorry, Mr Speaker.

Oral Answers to Questions

Alistair Carmichael Excerpts

Tuesday 4th July 2017 Commons Chamber

The Secretary of State was asked—

[Mr Alistair Carmichael (Orkney and Shetland) (LD)]

1. What recent discussions he has had with the Home Secretary on ensuring that the NHS has the workforce it needs after the UK leaves the EU.

[The Secretary of State for Health (Mr Jeremy Hunt)]

The 150,000 EU nationals working in our health and care services do a brilliant job and we want them to continue doing it. I am in regular talks with Cabinet colleagues to inform both domestic workforce plans and the Government’s negotiations with the EU.

[Mr Carmichael]

The Secretary of State will be aware that that figure represents in excess of 5% of the total workforce in the NHS. This matter will have to be addressed, engaging with the recruitment sector, the employment sector and, indeed, the devolved Administrations. Is that how he will handle it?

[Mr Hunt]

We absolutely will be taking a UK-wide approach. The numbers for England are actually slightly higher than those the right hon. Gentleman talks about—about 9% of doctors and about 19% of nurses are EU nationals. However, we are still seeing doctors and nurses coming to the UK, and we need to do everything in all parts of this House to reassure them that we see them as having a bright and vital future in the NHS.